Global corporate updates: Evotec, Kymera, and Eloxx report financial outlooks and analyst ratings

Several companies in the biotechnology and services sectors have released financial updates and analyst ratings.

Evotec has maintained its annual revenue forecast of 570 to 610 million euros, though it expects an adjusted EBITDA loss between 70 and 105 million euros. In the biotech space, Eloxx Pharmaceuticals received an Outperform rating from Leerink Partners with a 32.00 USD price target, following progress in its Phase 2b EXACT study for Exaluren. Kymera Therapeutics also received an Outperform rating from Raymond James with a 140.00 USD target, driven by expectations for its KT-621 candidate.

Conversely, Wall Street Zen downgraded RxSight, Inc. to Sell, despite the company exceeding revenue consensus in the second quarter. In the logistics and services sector, SATS Ltd. announced its next semi-annual results date for November 11, 2026, following a first-quarter revenue increase of 11.30 percent.